Recently, angiotensin II (Ang II) has been shown to cause hypertrophy of cultured quiescent rat aortic smooth muscle (RASM) cells. This observation along with the demonstration of angiotensinogen mRNA in the vessel wall has led us to postulate a role for vascular angiotensin in hypertensive blood vessel hypertrophy. To investigate further the possible molecular mechanisms, we examined the effect of Ang II on the expression of two genes known to be involved with cellular growth response. Near-confluent RASM cells were made quiescent by 48-h exposure to a defined serum-free medium. Ang
Introduction
One of the major structural adaptations to an elevated blood pressure is the growth of vascular smooth muscle. It has been proposed that this structural change may play an important role in amplifying and perpetuating hypertension (1) . Mor- phologic studies demonstrated that in the aorta this increase in smooth muscle mass is due to hypertrophy rather than hyperplasia (2) , whereas in the smaller-resistance vessels hyperplasia may be the principal process (3) . The factors that initiate and maintain the vascular growth response have not been fully elucidated. The hypertrophy seen in the aorta may be a response, at least in part, to hemodynamic forces since it has been shown that the reduction in blood pressure ofthe spontaneously hypertensive rat (SHR)1 with nonspecific vasodilators (e.g., hydralazine) prevents, in part, the increase in smooth muscle mass (4) . However, evidence also suggests that nonhemodynamic factors may play a role in the vascular hypertrophy Qf hypertension. A leading candidate for such a humoral factor is angiotensin II (Ang II). The blockade of Ang II production with a converting-enzyme inhibitor, captopril, in the SHR results in a reduction in smooth muscle hypertrophy which is significantly greater than that observed for a comparable reduction in blood pressure with hydralazine treatment (4) . Indeed, the direct stimulating effect of Ang II on vascular myocyte growth has been demonstrated by Geisterfer et al. (5) using cultured rat aortic smooth muscle cells and by Campbell-Boswell and Robertson (6) using cultured human aortic smooth muscle cells.
In recent years evidence has been accumulating that the protooncogenes are important regulators of cell growth (7, 8) . Numerous investigators have demonstrated that, when quiescent cells in culture are stimulated to grow by the addition of serum or specific growth factors, rapid and transient inductions ofthe protooncogenes c-fos and c-myc (7-1 1) occur. Furthermore, the inhibition of c-fos mRNA translation by antisense c-fos transcription has been shown to inhibit fibroblast growth (12, 13) . Since it has been reported that angiotensin can induce c-fos mRNA expression in the rat aortic smooth muscle cells (14, 15) , it is a logical extension to explore the influence of angiotensin on c-myc expression. In addition, the smooth muscle mitogen, platelet-derived growth factor (PDGF) has been shown recently to be expressed in vascular smooth muscle cells (16) and postulated to be involved in the autocrine regulation ofthe growth ofthese cells. We believe that it would be additionally important to study whether PDGF expression is involved in the smooth muscle growth responses to angiotensin. We report herein that Ang II leads to a rapid increase in the expression of the protooncogene c-myc mRNA. A delayed induction of PDGF A-chain mRNA accompanied by an increase in PDGF secretion is also observed. Taken together, these findings may have important implications in the mechanism of Ang II on the development of the increased smooth muscle mass seen in hypertension.
Methods
Cell culture. Rat aortic smooth muscle cells (RASM) (passages [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] were produced according to the method of Gunther et al. (17) and maintained in Dulbecco's modified Eagle's medium (DME, Gibco, Grand Island, NY) with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 ,ug/ml) and 25 mM Hepes, pH 7.4. Cells were incubated at 37°C in a humidified atmosphere of 95% air/5% CO2. In preparation for experiments, the cells were made quiescent by placing them in a defined serum-free medium containing insulin (5 X 10-7 M, Sigma Chemical Co., St. Louis, MO), transferrin (5 gg/ml, Sigma Chemical Co.), and ascorbate (0.2 mM, Sigma Chemical Co.). This medium has been shown by others to maintain smooth muscle cells in a quiescent, noncatabolic state for an extended period of time (18) . Ang II and [Sar-l, Ala-8]-Ang II (saralasin) were dissolved in 20 mM acetic acid at a concentration of 2 mg/ml. Cycloheximide was dissolved in distilled water at a final concentration of 4 mg/ml. These compounds were added independently or together, to the media of cultured RASM at zero time.
RNA isolation. Cells were harvested at the indicated time points by the addition of 0.05% trypsin and 0.53 mM EDTA. The detached cells were pellet by centrifugation at 2,000 rpm for 10 min, frozen in liquid nitrogen, and stored at -70°C until used. Total RNA was isolated as described (19) Gels were baked in a vacuum oven at 80°C for 2 h and prehybridized at 420C for 3-4 h in a buffer containing 5X Denhardt's, 5X SSC, 50% formamide, 1% SDS, 200 ug/ml salmon sperm DNA, 100 Mg/ml yeast tRNA, and 1.0 Mg/ml each of poly A and poly C. The blots were then hybridized in the same buffer at 420C overnight with 32P-labeled DNA. After hybridization the blots were washed at room temperature in 2X SSC, 0.1% SDS and then with 0.2X SSC, 0.1% SDS at 650C. Autoradiograph was performed with Kodax XAR-5 film with intensifying screens (DuPont Co., Wilmington, DE) at -70'C. The developed film was then scanned with a microdensitometer (LKB Instruments, Inc., Gaithersburg, MD). Labeling ofcDNA. The following probes were used: (a) the mouse c-myc full-length cDNA (20); (b) the human PDGF A-chain full-length cDNA (kindly supplied by Dr. C.-H. Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden) (21); and (c) a 1.2-kb Pst fragment of the v-sis gene (22) . DNA probes were labeled with 25 MCi of [32P]deoxycytidine 5'-triphosphate (1,000-1,500 Ci/mmol; New England Nuclear) using the random oligonucleotide method as described (23) . The 32P-labeled DNA was purified by Sephadex G-50 chromatography.
Determination ofPDGF concentration. 24 h after addition of angiotensin or vehicle, the culture media were collected. The PDGF concentrations in the media were measured directly by a radioreceptor assay (24) ,ug/ml). Cycloheximide had no effect on baseline c-myc mRNA levels in unstimulated cells (data not shown). In contrast, cycloheximide resulted in a greater and more prolonged increase of the c-myc mRNA (Fig. 2 A) (Fig. 1 B) . The level peaked at 9 h and persisted until 11 h after exposure to Ang II. The induction of PDGF A-chain gene expression by Ang II was dose-dependent (Fig. 3, left and  middle) . The lowest concentration of Ang II capable of stimulating PDGF A-chain mRNA expression was 10-" M. The EC50 was 10-9 M. The effect was Ang II receptor-specific in that it was completely blocked by the Ang II antagonist, saralasin (Fig. 3, right) . In contrast to the result with c-myc mRNA, the blockade of protein synthesis with cycloheximide completely inhibited the induction of PDGF A-chain by Ang II (Fig. 2 B) . However, cycloheximide alone had no effect on the baseline expression of PDGF A-chain mRNA in unstimulated cells.
Effects ofAng II on the release ofPDGF by RASM. Under basal conditions, quiescent RASM cells secrete low levels of PDGF (0.15±0.06 ng/ml per 24 h). However, in response to Ang II, this increases 15-20-fold (2.15±0.05 ng/ml per 24 h, n = 3, P < 0.001, Fig. 4 ). In this assay the PDGF employed as the radiogland and in the standard curve was the A-B heterodimer. 
Discussion
In these studies we have demonstrated that the potent vasoconstrictor Ang II can induce the expression of the protooncogene c-myc along with the gene encoding the A-chain of PDGF. In addition, angiotensin has been shown to induce c-fos mRNA expression (14, 15) . Our data demonstrate that the increase in c-myc mRNA expression does not require protein synthesis and occurs within 30 min after the addition of Ang II. In contrast, the increase in PDGF A-chain mRNA occurs 4-6 h after the addition of Ang II and requires protein synthesis. These molecular responses are dose-dependent and are specific since they can be blocked by the specific Ang II inhibitor, saralasin.
In recent years it has become clear that the protooncogene c-myc is an important regulator of cell growth (7, 8) and is activated in numerous cell types in response to growth-promoting agents (7-1 1) . In addition, cultured smooth muscle cells are capable of producing PDGF A-A homodimer (26, 27) . In this study, angiotensin stimulated the synthesis and release of PDGF A chain by these cells. Since the A-A homodimer of PDGF is mitogenic towards smooth muscle cells (26) sions seen in this study may, in part, mediate the growth promoting effect of Ang II.
An interesting issue raised by these observations is that, although Ang II induces the expressions of c-myc and PDGF A-chain mRNA, Geisterfer et al. (5) demonstrated that Ang II induces hypertrophy and tetraploidy but not hyperplasia. This suggests that although the induction of these factors by Ang II confers competence on the smooth muscle cells, it is insufficient to stimulate the cells to go through mitosis. The explanation for this observation is not clear. Since only PDGF A-A homodimer is stimulated by Ang II, the data suggest that the A-A homodimer is a less potent mitogen than its A-B or B-B counterparts. Indeed, Heldin et al. (25) and Escobeda et al. (28) have showed recently that the A-A homodimer is a less potent mitogen of fibroblast cells than the B-B homodimer or the A-B heterodimer. However, it should also be pointed out that, under a different culture condition (presence of serum) and using vascular smooth muscle cell from a different species, angiotensin has been reported to induce cellular hyperplasia (6) . Thus, the growth response to angiotensin may be depen- dent on the culture condition (e.g., other growth factors) and/ or the cell type. The elucidation ofthe mechanisms responsible for cellular hypertrophy vs. hyperplasia is a fundamental problem in cell biology (29) .
If Ang II is responsible in part for the hypertensive smooth muscle growth, it is necessary to postulate a mechanism by which Ang II is activated in chronic hypertension. In most forms of chronic hypertension, e.g., SHR, plasma renin levels are normal or even low (30, 31) , thus making it difficult to propose that an elevation of plasma Ang II levels is responsible for the smooth muscle growth. Yet, angiotensin-converting enzyme inhibition prevents vascular hypertrophy in these rats. Recently all ofthe components ofthe renin angiotensin system have been demonstrated to be present in the vascular wall (30, 32) . Since the angiotensinogen gene has been shown to be expressed in the thoracic aortic smooth muscle cell layer (33) as well as in the periadventitial fat tissue (32, 34) , one may propose an autocrine or paracrine mechanism of angiotensin for the stimulation of smooth muscle cell growth. In some experimental models of hypertension, there is evidence to suggest that this tissue renin-angiotensin system is activated (31, 35) . Therefore, it is attractive to speculate that increased vascular angiotensin production is involved in the vascular hypertrophy seen in these animals.
The data presented herein also demonstrate that protein synthesis is not necessary for the increase in the expression of c-myc mRNA. The mechanism of PDGF A-chain mRNA increase appears to be different since it is activated much later and its induction is blocked by the inhibition of protein synthesis. Since c-myc encodes a nuclear protein (36) it is possible that it may play a direct role in the induction of PDGF Achain expression, but we cannot rule out the possibility that other genes are also activated by Ang II and take part in the induction of PDGF A-chain expression. Our data do not indi- cate at what molecular level Ang II acts to increase the mRNAs of the genes studied. In most systems c-fos appears to be under transcriptional control (8, 9) and there is some data to suggest that c-myc is under postranscriptional control in serum activated smooth muscle cells (37) . Since the cDNA for PDGF A-chain has only recently been cloned, the level at which its expression is controlled has not been studied. The Ang II-induced PDGF expression in RASM may be a useful system to examine this question.
In summary, our data demonstrate that along with many properties (including vasoconstriction, thirst stimulation, and stimulation of aldosterone secretion), angiotensin may also be an important growth-promoting agent of vascular smooth muscle cells. A broader implication of the results of this study may be that vasoactive hormones are potentially growth-promoting substances and may participate in hypertension by inducing hypertrophy as well as vasoconstriction. To our knowledge this is the first demonstration that PDGF expression is influenced by a vasoactive substance. The molecular mechanism by which Ang II stimulates c-myc and PDGF Achain mRNAs and the role of these genes in vascular hypertrophy will be the important subjects of future investigations.
